Physician profile
Ryan D Simonak
NPI 1871721993
$10,215.60
in general payments reported to CMS, 2019-2025
62 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $1,223 · 2021: $1,614 · 2022: $1,570 · 2023: $1,759 · 2024: $1,817 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,903 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,902.65 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $944.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $711.14 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $701.77 | 2019-2025 | Jardiance |
| Pfizer INC. | $614.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $597.56 | 2019-2024 | Cycloset, Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $575.19 | 2019-2024 | Farxiga, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $414.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $388.89 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $383.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $323.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $289.61 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $258.89 | 2019-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $176.52 | 2019-2022 | |
| Avvisto Therapeutics, LLC | $175.00 | 2024-2025 | Cycloset |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Simonak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.